Gelonghui, May 23 | According to a recent research report by Tianfeng Securities, Zhifei Biotech (300122.SZ) grew steadily in 2023, and the 2024Q1 performance was under pressure. It is believed that as the HPV vaccine release and recombinant herpes vaccine contributed to sales growth, the performance may be expected to remain relatively stable and maintain a “buy” rating. In 2023, 36.55 million nine-valent HPV vaccine batches were issued, +136.16% year over year; 10.34 million quadrivalent HPV vaccine batches were issued, -26.27% year over year. In October 2023, the company and GSK reached cooperation for the first time. The company will act as an agent to promote and sell the recombinant shingles vaccine in mainland China, and the two sides reached preliminary intentions for future promotion cooperation for the RSV vaccine in mainland China.
研报掘金丨天风证券：维持智飞生物“买入”评级 重组带疱疫苗销售值得期待
Research Nuggets丨Tianfeng Securities: Maintaining Zhifei Biotech's “Buy” Rating and Sales of Recombinant Herpes Vaccine Is Worth Looking Forward to
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.